Table 1 Clinical characteristic of patients with leukemia
Patient | Age, years/sex | WBC count (×109) | Diagnosis | Mutations | Initial or relapsed disease | IC50for Tenovin-6, μM |
|---|---|---|---|---|---|---|
1 | 11/M | 216.45 | ALL-L2, B | BCR/ABL (+, 72%) | Initial | 5.44 |
2 | 4/M | 1.09 | ALL-L2, B | Neg | Initial | 14.65 |
3 | 3/F | 4.27 | ALL-L2, B | Neg | Initial | 8.05 |
4 | 10.6/M | 17.66 | ALL-L2, B | Neg | Initial | 4.7 |
5 | 0.6/M | 23.16 | ALL-L2, B | Neg | Initial | 2.72 |
6 | 10/F | 531 | ALL-L2, T | Neg | Initial | 7.49 |
7 | 2.3/F | 14.97 | ALL-L2, B | MLL (+, 82%) | Initial | 7.15 |
8 | 10/M | 22.98 | ALL-L2, T | Neg | Initial | 10.49 |
9 | 10.6/M | 17.66 | ALL-L2, B | Neg | Initial | 2.03 |
10 | 2.4/F | 24 | ALL-L2, B | Neg | Relapsed | 5.9 |
11 | 10/M | 43.8 | ALL-T | Neg | Relapsed | 4.5 |
12 | 1.9/M | 44.2 | ALL-L2, B | Neg | Initial | 3.03 |
13 | 3.5/F | 5.2 | AML-M0 | Neg | Initial | 8.15 |
14 | 1.6/F | 5.1 | AML-M7 | Neg | Initial | 3.08 |
15 | 3/M | 4.27 | ALL-L2, B | Neg | Initial | 2.88 |
16 | 2/M | 58.9 | ALL-L1, B | unknown | Initial | 4.03 |
17 | 13/M | 5.66 | ALL-L2, B | Neg | Relapsed | 6.98 |
18 | 9.5/M | 10.59 | ALL-L2, B | Neg | Initial | 7.21 |
19 | 0.7/M | 43 | ALL-L2, B | Neg | Initial | 13.82 |
20 | 7/M | 6.55 | ALL-L2, B | Neg | Relapsed | 17 |
21 | 0.2/M | 54.83 | ALL-L2, B | MLL (+, 86%) | Initial | 4.83 |
22 | 0.5/M | 208.85 | ALL-L2, B | Neg | Initial | 3.8 |
23 | 0.8/F | 137.41 | ALL-L2, B | MLL (+, 96%) | Initial | 7.24 |
24 | 11/M | 24.06 | ALL-L2, B | Neg | Initial | 3.91 |
25 | 11/M | 56.8 | ALL, mature B | Neg | Initial | 4.26 |
26 | 2/F | 281.31 | ALL-L1, T | Neg | Initial | 4.13 |
27 | 10/F | 34.7 | AML-M3b | PML-RARa (+, 35%) | Initial | 7.83 |
28 | 3/F | 8.07 | ALL-L2, B | TEL/AML1 (+, 85%) | Initial | 3.58 |
29 | 14.2/M | 104 | ALL-L2, B | BCR/ABL (+, 82%) | Initial | 3.75 |
30 | 12/M | 384 | ALL-L2, B | Neg | Initial | 8.16 |
31 | 4/M | 2.01 | ALL-L2, B | TEL/AML (+, 75%) | Initial | 6.15 |
32 | 12/M | 189 | ALL-L2, T | Neg | Initial | 7.07 |
33 | 1.5/F | 4.7 | ALL-L2, B | Neg | Initial | 4.74 |
34 | 2/F | 26.7 | ALL | Neg | Initial | 5.32 |
35 | 9/F | 3.8 | ALL-L2, B | Neg | Initial | 12.48 |
36 | 4.2/M | 17.4 | ALL-L2, B | Neg | Initial | 6.2 |
37 | 6/F | 52.53 | ALL-L2, B | TEL/AML (+) | Initial | 3.35 |
38 | 8/M | 8.95 | ALL-T | Neg | Initial | 4.31 |
39 | 8/M | 34.3 | ALL-L2, B | Neg | Initial | 4.03 |
40 | 5/M | 26.46 | ALL-L2, B | Neg | Initial | 12.56 |
41 | 9/M | 3.29 | ALL-L2, B | Neg | Initial | 10.2 |
42 | 1/M | 21.6 | AML | Neg | Initial | 14.75 |
43 | 12/M | 82.79 | ALL-L1, T | Neg | Initial | 6.65 |
44 | 4/M | 6.62 | Lymphoma | Unknown | Initial | 4.81 |
45 | 0.8/F | 137.41 | ALL-L2 | MLL (+, 96%) | Initial | 13.22 |
46 | 11/M | 24.06 | ALL-L2 | Neg | Initial | 16.38 |
47 | 55/F | 62.75 | ALL | Neg | Initial | ND |
48 | 28/F | 2.65 | ALL | Neg | Initial | ND |